Vir Biotechnology Stock Total Asset
| VIR Stock | USD 6.95 0.02 0.29% |
Vir Biotechnology fundamentals help investors to digest information that contributes to Vir Biotechnology's financial success or failures. It also enables traders to predict the movement of Vir Stock. The fundamental analysis module provides a way to measure Vir Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vir Biotechnology stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 1.4 B | 1.4 B | |
| Intangibles To Total Assets | 0.02 | 0.02 |
Vir | Total Asset |
Vir Biotechnology Company Total Asset Analysis
Vir Biotechnology's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Vir Biotechnology Total Asset | 1.4 B |
Most of Vir Biotechnology's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vir Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Vir Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Vir Biotechnology is extremely important. It helps to project a fair market value of Vir Stock properly, considering its historical fundamentals such as Total Asset. Since Vir Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vir Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vir Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Vir Total Asset Historical Pattern
Today, most investors in Vir Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vir Biotechnology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vir Biotechnology total asset as a starting point in their analysis.
Vir Biotechnology Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Vir Total Assets
Total Assets |
|
Based on the latest financial disclosure, Vir Biotechnology has a Total Asset of 1.4 B. This is 81.4% lower than that of the Biotechnology sector and 29.2% lower than that of the Health Care industry. The total asset for all United States stocks is 95.25% higher than that of the company.
Vir Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vir Biotechnology's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vir Biotechnology could also be used in its relative valuation, which is a method of valuing Vir Biotechnology by comparing valuation metrics of similar companies.Vir Biotechnology is currently under evaluation in total asset category among its peers.
Vir Biotechnology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Vir Biotechnology from analyzing Vir Biotechnology's financial statements. These drivers represent accounts that assess Vir Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vir Biotechnology's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 3.2B | 5.4B | 3.4B | 1.3B | 1.0B | 1.8B | |
| Enterprise Value | 2.8B | 5.2B | 2.6B | 1.2B | 777.9M | 739.0M |
Vir Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vir Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vir Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Vir Biotechnology Institutional Holders
Institutional Holdings refers to the ownership stake in Vir Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vir Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vir Biotechnology's value.| Shares | Renaissance Technologies Corp | 2024-12-31 | 1.2 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.1 M | Baker Bros Advisors Lp | 2024-12-31 | 1.1 M | Sio Capital Management, Llc | 2024-12-31 | 1.1 M | Northern Trust Corp | 2024-12-31 | 930.5 K | Artisan Partners Limited Partnership | 2024-12-31 | 918.5 K | Ikarian Capital, Llc | 2024-12-31 | 897.9 K | Hudson Bay Capital Management Lp | 2024-12-31 | 849.9 K | Point72 Asset Management, L.p. | 2024-12-31 | 848.5 K | Sb Investment Advisers (uk) Ltd | 2024-12-31 | 16.7 M | Blackrock Inc | 2024-12-31 | 16.5 M |
Vir Fundamentals
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (8.33) % | ||||
| Current Valuation | 153.23 M | ||||
| Shares Outstanding | 137.14 M | ||||
| Shares Owned By Insiders | 12.01 % | ||||
| Shares Owned By Institutions | 76.70 % | ||||
| Number Of Shares Shorted | 7.67 M | ||||
| Price To Earning | 3.16 X | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 12.95 X | ||||
| Revenue | 74.2 M | ||||
| Gross Profit | (404.44 M) | ||||
| EBITDA | (537.61 M) | ||||
| Net Income | (521.96 M) | ||||
| Cash And Equivalents | 2.2 B | ||||
| Cash Per Share | 16.55 X | ||||
| Total Debt | 90.14 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 4.79 X | ||||
| Book Value Per Share | 8.40 X | ||||
| Cash Flow From Operations | (446.35 M) | ||||
| Short Ratio | 6.31 X | ||||
| Earnings Per Share | (3.83) X | ||||
| Price To Earnings To Growth | 1.14 X | ||||
| Target Price | 32.0 | ||||
| Number Of Employees | 408 | ||||
| Beta | 1.17 | ||||
| Market Capitalization | 960.69 M | ||||
| Total Asset | 1.4 B | ||||
| Retained Earnings | (759.78 M) | ||||
| Working Capital | 922.8 M | ||||
| Net Asset | 1.4 B |
About Vir Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vir Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vir Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vir Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Vir Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vir Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving together with Vir Stock
Moving against Vir Stock
The ability to find closely correlated positions to Vir Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vir Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vir Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vir Biotechnology to buy it.
The correlation of Vir Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vir Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vir Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vir Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.